Gilead Sciences FY2025 EPS Increased by Cantor Fitzgerald

Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) - Stock analysts at Cantor Fitzgerald boosted their FY2025 EPS estimates for shares of Gilead Sciences in a research report issued on Wednesday, February 19th. Cantor Fitzgerald analyst O. Brayer now expects that the biopharmaceutical company will post earnings of $7.98 per share for the year, up from their previous estimate of $7.24. Cantor Fitzgerald currently has a "Neutral" rating and a $80.00 price objective on the stock. The consensus estimate for Gilead Sciences' current full-year earnings is $7.95 per share.

Several other brokerages have also issued reports on GILD. BMO Capital Markets boosted their price target on shares of Gilead Sciences from $110.00 to $115.00 and gave the company an "outperform" rating in a report on Wednesday, February 12th. Deutsche Bank Aktiengesellschaft raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and boosted their price target for the company from $80.00 to $120.00 in a report on Tuesday, February 18th. Truist Financial upped their target price on shares of Gilead Sciences from $83.00 to $97.00 and gave the stock a "hold" rating in a research note on Friday, November 8th. Maxim Group lowered shares of Gilead Sciences from a "buy" rating to a "hold" rating in a research note on Friday, November 8th. Finally, Wolfe Research assumed coverage on shares of Gilead Sciences in a research note on Friday, November 15th. They issued an "outperform" rating and a $110.00 target price for the company. Eleven investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have given a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $102.08.

Gilead Sciences Trading Down 0.1 %

Shares of GILD stock traded down $0.08 on Friday, hitting $109.95. The stock had a trading volume of 9,729,048 shares, compared to its average volume of 7,379,648. Gilead Sciences has a twelve month low of $62.07 and a twelve month high of $111.03. The firm has a market cap of $137.03 billion, a P/E ratio of 297.16, a PEG ratio of 0.71 and a beta of 0.18. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. The company has a fifty day moving average price of $95.41 and a two-hundred day moving average price of $88.73.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be issued a $0.79 dividend. This is a boost from Gilead Sciences's previous quarterly dividend of $0.77. This represents a $3.16 annualized dividend and a yield of 2.87%. The ex-dividend date is Friday, March 14th. Gilead Sciences's dividend payout ratio is currently 832.43%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, Director Jeffrey Bluestone sold 6,788 shares of the stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total transaction of $620,355.32. Following the transaction, the director now owns 8,920 shares in the company, valued at $815,198.80. This represents a 43.21 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $104.09, for a total transaction of $260,225.00. Following the transaction, the chief financial officer now owns 169,061 shares in the company, valued at approximately $17,597,559.49. The trade was a 1.46 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 713,000 shares of company stock valued at $67,945,181 in the last three months. 0.16% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in GILD. AMF Tjanstepension AB grew its position in shares of Gilead Sciences by 14.7% during the 3rd quarter. AMF Tjanstepension AB now owns 400,819 shares of the biopharmaceutical company's stock worth $33,645,000 after purchasing an additional 51,390 shares in the last quarter. Swedbank AB boosted its position in shares of Gilead Sciences by 10.2% during the 3rd quarter. Swedbank AB now owns 2,047,609 shares of the biopharmaceutical company's stock worth $171,672,000 after acquiring an additional 189,622 shares in the last quarter. nVerses Capital LLC acquired a new stake in shares of Gilead Sciences during the 3rd quarter worth approximately $25,000. Eastern Bank acquired a new stake in shares of Gilead Sciences during the 3rd quarter worth approximately $90,000. Finally, BLB&B Advisors LLC acquired a new stake in shares of Gilead Sciences during the 3rd quarter worth approximately $221,000. Institutional investors and hedge funds own 83.67% of the company's stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.